SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CollaGenex (CGPI) FDA PENDING -- Ignore unavailable to you. Want to Upgrade?

To: thomas larkin who wrote (27)4/18/1998 6:32:00 AM
From: Vector1  Respond to of 142
 
the amount of antibiotic in periostat is too small to kill bacteria thus there should be no issue of resistance. The company has submitted a ton of info on this to the FDA. Periostat works by inhibiting the enzyme that breaks down the gum tissue, not by killing the bacteria. Your point is well taken in that the fear on this point is depressing the stock IMO.
V1



To: thomas larkin who wrote (27)4/18/1998 9:01:00 PM
From: Tom D  Read Replies (1) | Respond to of 142
 
Resistance is not an issue....

because the amount of antiobiotic given is insufficient to kill vulnerable bacteria and select out the resistant organisms. With this dose range, all susceptible bacteria presumably are unaffected. But the small doses are capable of inhibiting the metalloproteinase enzymes which medicate periodontal disease.

If I have failed to clarify this, please respond.

Best Regards,
Tom D


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News